Últimas noticias sobre Illumina (NASDAQ:ILMN) Bolsa

Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

News

ABSI

ACCD

ARKG

ARKK

ARKQ

ARKX

ESLT

ILMN

NTLA

OKLO

PATH

Descubre las recientes decisiones de Ark Invest en energía, defensa y genética, con transacciones millonarias en empresas clave.

Ark Invest adquiere y vende acciones clave en energía, defensa y tecnología genética

Illumina Inc

Illumina Inc COM-WHEN ISSUED

Illumina's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NYSE">ILMN</a>) short percent of float has risen 18.33% since its last report. The company recently reported that it has 5.97 million shares sold short, which is 4.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Illumina Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738254616_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Illumina has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Illumina's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Illumina's peer group average for short interest as a percentage of float is 5.26%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Illumina?

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 9.5% on an annualized basis producing an average annual return of 17.91%. Currently, Illumina has a market capitalization of $21.89 billion. 
Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $2,715.56 today based on a price of $138.05 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738017928_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Accolade Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>), Deere &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>), Intellia Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), Cameco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>), Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>), and Absci Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>).
The trades include defense and energy companies, which have been in focus since the inauguration of Donald Trump. The President signed orders on Monday aimed at making it cheaper for companies to produce oil and gas, which could have an impact on energy companies. Defense stocks have also been in focus due to expectations of a pro-Israel stance from the new administration.
The NTLA Trade
The Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) collectively purchased 91,889 shares of Intellia Therapeutics Inc. Based on the closing price of $9.94, the total value of the trade amounts to approximately $913,580.06. This move indicates Ark&#8217;s continued confidence in the gene-editing sector.
The PATH Trade
Ark Invest sold 21,879 shares of UiPath Inc. through its ARKK fund. Given the closing price of $13.33, the trade is valued at around $291,712.07. This sale suggests a shift in Ark&#8217;s stance on the automation software company.
The DE Trade
Ark Invest&#8217;s ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) purchased a total of 3,474 shares of Deere &amp; Co. With the closing price at $463.15, the trade is worth approximately $1,607,571.10.
The CCJ Trade
Ark Invest also bought 17,504 shares of Cameco Corp (CCJ) through its ARKQ fund, valued at approximately $937,589.44 at the closing price of $53.56.
Other Key Trades:
<ul>
<li>Oklo Inc: Ark Invest sold 50333 shares through ARKQ.</li>
<li>Elbit Systems: Ark Invest Sold 2074 shares through ARKQ and 627 shares through ARKX.</li>
<li>Illumina Inc: Ark Invest bought 15876 shares through ARKG.</li>
<li>Absci Corp: Ark Invest bought 79411 shares through ARKG.</li>
<li>Accolade Inc: Ark Invest sold 466,337 shares through ARKG.</li>
</ul>
Photo courtesy: Ark Invest

Cathie Wood's Ark Invest Buys Into Defense And Energy Stocks Amid Trump's Inaugural Policies

On Tuesday, Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) raised its fourth-quarter revenues outlook to $1.10 billion, compared with a <a target="_blank" href="https://www.prnewswire.com/news-releases/illumina-reports-financial-results-for-third-quarter-of-fiscal-year-2024-302295734.html" rel="noreferrer noopener">prior view</a> <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">of $1.07&nbsp;billion</a>. The street view also stands at $1.072 billion. The current outlook represents 1% growth year over year.
The company&#8217;s full-year revenue for 2024 is approximately&nbsp;expected to be $4.33 billion&nbsp;versus the analyst consensus estimate of $4.304 billion, down 2% year over year. It previously expected it to fall 3% year over year.
For the fourth quarter of 2024, the company expects adjusted diluted earnings per share in the range of approximately 91 cents to 93 cents versus the street view of 91 cents.
For the full year 2024, the adjusted diluted EPS is projected to be between $4.12 and $4.14, versus the analyst consensus estimate of $4.13 (prior view:&nbsp;$4.05 &#8211; $4.15&nbsp;).
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/01/42974739/wall-street-rebounds-as-producer-inflation-misses-estimates-tesla-gains-chinese-stocks-rally" rel="noreferrer noopener">Wall Street Rebounds As Producer Inflation Misses Estimates, Tesla Gains, Chinese Stocks Rally</a>
The company expects a non-GAAP operating margin of approximately 19.7% for the fourth quarter of 2024 and around 21.3% for the full year (prior view: 21% &#8211; 21.5%).
For 2024, the company expects cash flow from operations of around $1.21 billion and free cash flow of about $1.07 billion.
For fiscal year 2025, it forecasts low single-digit revenue growth in constant currency, with reported revenue between $4.28 billion and $4.4 billion, a non-GAAP operating margin of approximately 23%, and a 10% growth in non-GAAP diluted EPS.
Yesterday, Illumina announced a collaboration with NVIDIA Corporation to enhance technology platforms for analyzing and interpreting multiomic data.
This partnership aims to speed up progress in clinical research, genomics AI development, and drug discovery. By combining Illumina&#8217;s sequencing and informatics tools with NVIDIA&#8217;s AI technology, the partnership&nbsp;seeks to improve <a target="_blank" href="https://www.benzinga.com//node/42945242" rel="noreferrer noopener">drug discovery and clinical development.</a>
Price Action: ILMN shares are trading lower by 3.94% to $138.54 at last check Tuesday.
Read now:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/01/42974082/nvidia-eyes-1-billion-in-healthcare-ai-revenue-next-growth-frontier" target="_blank" rel="noreferrer noopener">Nvidia Eyes $1 Billion In Healthcare AI Revenue: Is This The Next Growth Frontier?</a></li>
</ul>
Photo via Shutterstock.

Equities

Guidance

Markets

Movers

General

Illumina Raises Q4 Revenue Outlook To $1.10 Billion, Exceeding Street Expectations; Sees Solid Margins

Illumina shares are trading lower after the company provided preliminary Q4 and FY24 financial results and FY25 guidance.

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2024 and preliminary outlook for fiscal year 2025 ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January&nbsp;14, 2025 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). The webcast can be accessed through Illumina's website at investor.illumina.com.
Core Illumina
<ul>
<li>Revenue of approximately $1.10 billion for Q4 2024, up 1% from Q4 2023</li>
<li>Revenue of approximately $4.33 billion for 2024, down 2% from 2023 (and on a constant currency basis)</li>
<li>GAAP operating margin of approximately 16.7% for Q4 2024 and 34.2% for 2024</li>
<li>Non-GAAP operating margin of approximately 19.7% for Q4 2024 and 21.3% for 2024</li>
<li>GAAP diluted EPS of approximately $0.77 - $0.79 for Q4 2024 and $5.65 - $5.67 for 2024</li>
<li>Non-GAAP diluted EPS of approximately $0.91 - $0.93 for Q4 2024 and $4.12 - $4.14 for 2024</li>
<li>Cash flow provided by operations of approximately $1.21 billion and free cash flow (cash flow provided by operations less capital expenditures) of approximately $1.07 billion for 2024</li>
<li>For fiscal year 2025, expect constant currency revenue growth in the low single digits (reported revenue in the range of approximately $4.28 billion to $4.4 billion), non-GAAP operating margin of approximately 23%, and non-GAAP diluted EPS growth of approximately 10%</li>
</ul>
As previously announced, the company expects to report its full fourth quarter and fiscal year 2024&nbsp;results following the close of market on Thursday, February 6, 2025. The unaudited results in this press release are preliminary and subject to the completion of accounting and annual audit procedures and are therefore subject to adjustment.

Earnings

Illumina Announces Preliminary Financials For Q4 2024 With $1.10B Revenue, 2024 Revenue At $4.33B, GAAP EPS $5.65-$5.67; Non-GAAP EPS $4.12-$4.14; Sees 2025 Revenue Outlook Of $4.28B-$4.4B, Non-GAAP Margin 23%, EPS Growth 10%

Nvidia Corp&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) products aren&#8217;t just about GPUs and gaming. The technology company is now making waves <a href="https://www.benzinga.com/topic/artificial-intelligence">in healthcare artificial intelligence</a>.
At J.P. Morgan's Healthcare Conference on Monday, analyst Harlan Sur emphasized Nvidia&#8217;s strategic positioning and highlighted key drivers for future growth. Here's why Wall Street and hospitals alike are paying attention.
<h2 class="wp-block-heading">AI Agents To The Rescue</h2>
With a looming shortage of up to 20 million healthcare workers, Nvidia is stepping in with AI-driven solutions like delivery robots and generative AI for clinical conversations. Sur noted the rising demand for such agentic AI solutions due to labor shortages, with Nvidia already partnering with firms like Intrivo and Abridge to deploy these technologies.
These &#8220;digital health agents&#8221; aren&#8217;t just futuristic toys—they&#8217;re becoming vital to filling critical workforce gaps. Partnerships with players like Intrivo and Abridge underscore the real-world traction Nvidia is gaining.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/01/42966492/jensen-huang-said-quantum-computing-is-20-years-away-but-nvidia-bets-big-on-strategic-hiring">Jensen Huang Said Quantum Computing Is 20 Years Away, But Nvidia Bets Big On Strategic Hiring</a>
<h2 class="wp-block-heading">Nvidia: Big Platforms, Bigger Ambitions</h2>
Nvidia's powerful datacenter platforms—Omniverse, Cosmos, and DGX Cloud—are pushing healthcare AI adoption to new heights. According to Sur, the flexibility Nvidia offers across on-premise, cloud-based, or hybrid models is helping drive enterprise adoption. 
With a projected $1 billion in annual recurring healthcare revenues by FY26, the company is tapping into a market worth hundreds of billions.
<h2 class="wp-block-heading">Nvidia&#8217;s Tech Meets Medicine</h2>
From drug discovery to robotics-assisted surgeries, Nvidia embeds AI across medical devices and hospital operations. Sur highlighted Nvidia&#8217;s use of Omniverse and Cosmos platforms for creating physics-aware virtual environments to train robots and develop medical technologies.
<h2 class="wp-block-heading">Genomics, Partnerships, Competitive Firepower</h2>
New collaborations with Iqvia Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) and Illumina Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) signal Nvidia's aggressive push to dominate healthcare AI. Sur noted these strategic partnerships as critical steps in Nvidia&#8217;s healthcare AI roadmap.
From drug discovery to genomic research, Nvidia aims to unlock breakthroughs that could reshape human health.
If Sur's projections hold, healthcare AI could be Nvidia's next billion-dollar play.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42967114/what-does-joe-bidens-last-minute-chip-export-restrictions-mean-for-nvidia-that-has-jensen-huang-led-ai-giant-up-in-arms">Joe Biden Vs. Jensen Huang: What White House&#8217;s New Chip Export Restrictions Mean For Nvidia That Has The AI Giant Up In Arms</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Health Care

Analyst Ratings

Tech

NVDA

Nvidia Eyes $1 Billion In Healthcare AI Revenue: Is This The Next Growth Frontier?

Morgan Stanley analyst Tejas Savant maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Equal-Weight and lowers the price target from $156 to $150.

Price Target

Morgan Stanley Maintains Equal-Weight on Illumina, Lowers Price Target to $150

Contracts

Illumina, NVIDIA To Collaborate To 'Decode Biology And Propel Precision Health;' Illumina Shares Spike Higher

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson &amp; Johnson, and Novartis. The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep&#x2122;, powered by SOMAmer&#xAE; technology, a next-generation sequencing (NGS) based solution that will help scale access to proteomic insights.

Illumina Launches Proteomics Pilot with 50,000 UK Biobank Samples, Partners with GSK, J&J, and Novartis

Cathie Wood-led&nbsp;Ark Invest&nbsp;made significant trades in five major companies on Friday: Recursion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Intellia Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), Cloudflare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), and Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The RXRX Trade
Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) purchased a substantial 264,596 shares of&nbsp;Recursion Pharmaceuticals.
The value of this trade, calculated from the closing price of $6.88, is approximately $1.82 million. This move comes despite RXRX&#8217;s stock closing at a 5.23% decrease on Friday.
The ILMN Trade
Ark Invest&#8217;s Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARK Innovation ETF both bought shares of&nbsp;Illumina Inc.
ARKG acquired 4038 shares, while ARKK purchased 11425 shares. The combined value of these trades, calculated from the closing price of $136.69, is approximately $1.97 million.
This move was made despite Illumina's stock closing at a 2.14% decrease on Friday.
See Also: <a href="https://www.benzinga.com/25/01/42931747/bitcoin-supercycle-incoming-says-economist-but-theres-a-catch">Bitcoin Supercycle Incoming, Says Economist, But There&#8217;s A Catch</a>
The NTLA Trade
Ark Invest&#8217;s Genomic Revolution ETF and ARK Innovation ETF both bought shares of&nbsp;Intellia Therapeutics.
ARKG acquired 41503 shares, while ARKK purchased 124799 shares.
The combined value of these trades, calculated from the closing price of $10.2, is approximately $1.46 million. This move was made despite NTLA&#8217;s stock closing at a 15.14% decrease on Friday.
Intellia Therapeutics announced a 27% workforce reduction on Friday to cut costs.
The NET Trade
Ark Invest&#8217;s Next Generation Internet ETF (ARKW) sold 7840 shares of&nbsp;Cloudflare.
The value of this trade, calculated from the closing price of $112.62, is approximately $882,608. This move was made despite NET&#8217;s stock closing at a 2.66% decrease on Friday.
The ADPT Trade
Ark Invest&#8217;s Genomic Revolution ETF sold 130,790 shares of&nbsp;Adaptive Biotechnologies.
The value of this trade, calculated from the closing price of $6.5, is approximately $850,135. This move was made despite ADPT&#8217;s stock closing at a 2.84% decrease on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931941/mark-zuckerberg-critiques-culturally-neutered-companies-advocates-for-masculine-energy-as-meta-cuts-dei-programs-">Mark Zuckerberg Critiques &#8216;Culturally Neutered&#8217; Companies, Advocates For &#8216;Masculine Energy&#8217; As Meta Cuts DEI Programs Post-Joe Rogan Appearance</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Ark Invest

ETFs

ADPT

RXRX

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 10.57% on an annualized basis producing an average annual return of 18.97%. Currently, Illumina has a market capitalization of $22.18 billion. 
Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $3,290.99 today based on a price of $139.84 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736268307_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Software upgrade advances complete workflow solutions
New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X, and enable newly released Illumina Single-Cell Prep
SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a cutting-edge software upgrade and new kits.
Now in the market for the first time, the single-flow-cell NovaSeq&nbsp;X Sequencing System offers the same high-quality flow cells and speed as the NovaSeq X Plus Sequencing System—Illumina's most rapidly adopted and utilized high-throughput sequencing platform to date—at a more accessible cost for labs with lower volume. The sequencers began shipping in December, and simultaneously the company introduced the software v1.3 upgrade for the NovaSeq X Series to elevate sequencing performance and advance data quality. Additionally, new NovaSeq X 25B 100- and 200-cycle kits began shipping in December, which will be key enablers of multiomic applications, including the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4335026-1&amp;h=3224067856&amp;u=https%3A%2F%2Fwww.illumina.com%2Fproducts%2Fby-type%2Fsequencing-kits%2Flibrary-prep-kits%2Fsingle-cell-rna-prep.html&amp;a=Illumina+Single-Cell+3%27+RNA+Prep">Illumina Single-Cell 3' RNA Prep</a> (Illumina Single Cell Prep), now available under Illumina's brand following the company's acquisition of Fluent.

Biotech

Illumina Announces NovaSeq X Updates With Single-Flow-Cell System, Software Upgrade, New Kits Enhancing Multiomic Capabilities

Illumina's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NYSE">ILMN</a>) short percent of float has fallen 9.53% since its last report. The company recently reported that it has 6.51 million shares sold short, which is 4.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Illumina Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735138812_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Illumina has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Illumina's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Illumina's peer group average for short interest as a percentage of float is 4.79%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

The stock market has a well-documented tendency to deliver gains during the final trading days of December, a phenomenon known <a href="https://www.benzinga.com/24/12/42667439/us-stocks-to-open-higher-on-shortened-trading-day-as-santa-clause-rally-period-begins-says-analyst">as the &#8220;Santa Claus rally.&#8221; </a>
This period of optimism has historically brought cheer to investors, with the S&amp;P 500 gaining in 64 out of the last 96 years during the Dec. 24–Dec. 31 window, averaging a respectable 0.85% return, according to data from Seasonax.
The Santa Claus rally's most memorable performance occurred in 2018, when the S&amp;P 500 surged 6.6%, its strongest year-end rally on record. Close on its heels was 1933, which delivered a 5.5% rally.
On the flip side, 1937 and 2000 stand out as exceptions, with losses of 4.6% and 2.4%, respectively, over the same period.
The pattern holds true even during election years, offering hope to traders as 2024 wraps up. In the past 24 election years, the S&amp;P 500 has posted gains in 15 instances, averaging a modest 0.7% return. Notable rallies occurred in 2008, with a 4% rise, and in 1928, when the index climbed 3.4%.
<h3 class="wp-block-heading">10 Santa Rally Hyper Responders</h3>
For traders looking to capitalize on this seasonal tailwind, certain stocks have consistently outperformed during the Santa Claus rally window.
Here are 10 notable S&amp;P 500 stocks that have historically shone between Dec. 24 and Dec. 31 over the last 20 years:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Avg. Return</th>
<th>Median Return</th>
<th>Max Profit</th>
<th>Max Loss</th>
<th>Win Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newmont Mining Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>+1.68%</td>
<td>+1.36%</td>
<td>+10.76%</td>
<td>-2.97%</td>
<td>65%</td>
</tr>
<tr>
<td>Illumina, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)</td>
<td>+1.49%</td>
<td>+1.25%</td>
<td>+10.08%</td>
<td>-2.64%</td>
<td>60%</td>
</tr>
<tr>
<td>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</td>
<td>+1.42%</td>
<td>+0.96%</td>
<td>+10.96%</td>
<td>-3.60%</td>
<td>60%</td>
</tr>
<tr>
<td>Assurant, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>)</td>
<td>+1.41%</td>
<td>+0.56%</td>
<td>+14.33%</td>
<td>-4.07%</td>
<td>65%</td>
</tr>
<tr>
<td>Mohawk Industries, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>)</td>
<td>+1.32%</td>
<td>+1.22%</td>
<td>+8.81%</td>
<td>-3.94%</td>
<td>65%</td>
</tr>
<tr>
<td>Global Payments Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)</td>
<td>+1.32%</td>
<td>+0.95%</td>
<td>+8.14%</td>
<td>-1.51%</td>
<td>75%</td>
</tr>
<tr>
<td>Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)</td>
<td>+1.28%</td>
<td>+0.52%</td>
<td>+9.27%</td>
<td>-2.89%</td>
<td>60%</td>
</tr>
<tr>
<td>Goldman Sachs Group, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)</td>
<td>+1.27%</td>
<td>+0.39%</td>
<td>+10.40%</td>
<td>-1.41%</td>
<td>70%</td>
</tr>
<tr>
<td>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>+1.25%</td>
<td>+1.13%</td>
<td>+9.63%</td>
<td>-4.70%</td>
<td>60%</td>
</tr>
<tr>
<td>Ralph Lauren Corp. (NYSE RL)</td>
<td>+1.19%</td>
<td>+0.51%</td>
<td>+8.21%</td>
<td>-2.36%</td>
<td>65%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data: Seasonax</figcaption></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42671903/investors-aggressively-bought-stocks-etfs-despite-fed-volatile-week-bank-of-america-reveals-largest-inflows-since-2017">Investors Aggressively Bought Stocks, ETFs In Volatile Fed Week: Bank Of America Reveals Largest Inflows Since 2017</a></li>
</ul>
Photo: Shutterstock

Education

Santa Claus Rally: 10 S&P 500 Stocks That Consistently Outperform During Year-End Optimism

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 10.11% on an annualized basis producing an average annual return of 18.44%. Currently, Illumina has a market capitalization of $21.57 billion. 
Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $2,976.69 today based on a price of $135.99 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735056016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years

It's the holiday season, but the stock market's festivities have been anything but cheerful this week.
At the week&#8217;s start traders were buoyed by a record-breaking Nasdaq 100 topping 22,000 and an optimistic outlook on interest rate cuts ahead <a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">of the Federal Reserve meeting</a>.
All signs pointed to the Santa Rally – a time Wall Street traditionally celebrates with stocks climbing during the final stretch of the year – making its grand entrance yet again in 2025.
Yet, just as traders were preparing for a festive year-end bull run, the Grinch arrived midweek to throw a wrench in the celebrations.
<h3 class="wp-block-heading">The Grinch Steals The Show</h3>
Wednesday marked a dramatic turn of events as the Federal Reserve's hawkish tone sent shockwaves through the markets. 
Chair Jerome Powell delivered a lump of coal to investors by declaring a "new phase" for monetary policy. While the Fed had already cut rates by 100 basis points since September, Powell hinted at a prolonged pause, citing rates moving &#8220;meaningfully&#8221; closer to neutral territory. 
The implications were clear: the days of aggressive cuts are over. Even worse than that, the Grinch didn&#8217;t rule out the possibility of a rate hike next year. This unexpected twist sent shivers down traders&#8217; spines, leaving markets rattled.
The CBOE Volatility Index or VIX – Wall Street's so-called fear gauge – spiked over 70% on Wednesday, its sharpest single-day surge since February 2018. 
The S&amp;P 500 and Dow Jones Industrial Average recorded their worst daily performances in over two years, while tech stocks sank like a stone in deep water.
Hopes for a Santa Rally seemed to crumble as the Grinch stole the show. 
<h3 class="wp-block-heading">A Christmas Miracle?</h3>
Just when it seemed all was lost, Friday brought a glimmer of hope—the kind of plot twist only a Christmas story could deliver. 
Fresh inflation data offered an unexpected gift to traders: the Fed's personal consumption expenditure (PCE) price index rose by 2.4% in November, falling short of the anticipated 2.5%. Even more encouraging, the core PCE, which excludes volatile food and energy prices, held steady at 2.8%, undercutting predictions of 2.9%.
This softer-than-expected inflation print was the equivalent to finding a shiny new toy under the tree.
Risk appetite rebounded swiftly, with traders rushing to scoop up the stocks battered during the week's earlier sell-off. 
Sentiment brightened, and with it, the Santa Rally narrative began to regain momentum.
<h3 class="wp-block-heading">The Santa Rally And Its Legacy</h3>
The stock market has a long-standing tendency to rally during the last trading days of December. 
According to data from Seasonax, the S&amp;P 500 has posted gains during the Dec. 20–Dec. 31 period in 76 out of the past 96 years, averaging a 1.92% return. Over the last eight years, this year-end rally has been remarkably consistent, delivering positive returns each time.
In the past three decades, the S&amp;P 500 has ended the year on a high note in 24 of 30 instances. Even the losses have been relatively mild, with the most recent December downturn occurring in 2022 when the index slipped by 1.8% during the final days.
With six trading days left in 2024, traders may still have time to save the Santa Rally.
<h3 class="wp-block-heading">10 Stocks To Watch For Year-End Gains</h3>
Looking back at 20 years of data, here are 10 standout names within the S&amp;P 500 index that have consistently delivered strong year-end performances: 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<th>Stock</th>
<th>Avg. Return</th>
<th>Max Gain</th>
<th>Max Loss</th>
<th>Win Ratio</th>
</tr>
<tr>
<td>Freeport-McMoRan Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>)</td>
<td>+3.63%</td>
<td>+14.63%</td>
<td>-13.51%</td>
<td>90%</td>
</tr>
<tr>
<td>Illumina, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)</td>
<td>+3.62%</td>
<td>+20.76%</td>
<td>-2.56%</td>
<td>80%</td>
</tr>
<tr>
<td>Newmont Mining Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>+3.37%</td>
<td>+16.14%</td>
<td>-3.66%</td>
<td>75%</td>
</tr>
<tr>
<td>The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>)</td>
<td>+3.29%</td>
<td>+13.26%</td>
<td>-5.98%</td>
<td>75%</td>
</tr>
<tr>
<td>Global Payments Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)</td>
<td>+3.06%</td>
<td>+9.31%</td>
<td>-2.12%</td>
<td>75%</td>
</tr>
<tr>
<td>CBRE Group, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>)</td>
<td>+2.94%</td>
<td>+13.46%</td>
<td>-2.25%</td>
<td>75%</td>
</tr>
<tr>
<td>Invesco Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>)</td>
<td>+2.80%</td>
<td>+10.23%</td>
<td>-2.83%</td>
<td>70%</td>
</tr>
<tr>
<td>ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>+2.73%</td>
<td>+11.45%</td>
<td>-3.78%</td>
<td>70%</td>
</tr>
<tr>
<td>Mohawk Industries, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>)</td>
<td>+2.60%</td>
<td>+13.58%</td>
<td>-6.57%</td>
<td>70%</td>
</tr>
<tr>
<td>Western Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</td>
<td>+2.59%</td>
<td>+22.24%</td>
<td>-3.78%</td>
<td>65%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42627985/which-magnificent-7-stock-will-gain-the-most-in-a-santa-claus-rally-28-select">Which Magnificent 7 Stock Will Do Best In Santa Claus Rally? Tesla Edged Out As 28% Select…</a></li>
</ul>
Photo: Courtesy of Shutterstock.

Macro Economic Events

Econ #s

Economics

Federal Reserve

CBRE

Traders Fight The Grinch To Save The Santa Rally: 10 S&P 500 Stocks Poised For A Year-End Surge

Super Micro Computer, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock is trading below its 50-day moving average as it awaits removal from the Nasdaq 100 Index on <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42494812/annual-changes-to-the-nasdaq-100-index" rel="noreferrer noopener">December 23, 2024</a>, joining the likes of Illumina, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)&nbsp;and&nbsp;Moderna, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), and Axon Enterprise Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) entered the coveted club as a replacement.
The Nasdaq-100 Index comprises 100 of the largest non-financial companies on The Nasdaq Stock Market.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42514598/hubspots-ai-powered-tools-set-to-drive-smb-growth-and-crm-innovation-analyst-says" rel="noreferrer noopener">HubSpot To Dominate SMB CRM Space With AI-Driven Platform, Says BofA Analyst</a>
Established in January 1985 alongside the Nasdaq Financial-100 Index, which tracks the 100 largest financial stocks on Nasdaq, these indexes serve as benchmarks for financial instruments like options, futures, and funds.
The Nasdaq-100 undergoes an annual reconstitution each December, aligned with the quadruple witching expiration on Friday of the quarter.
Super Micro Computer stock plunged 62% in the last six months. Reportedly, the AI server company has <a target="_blank" href="https://www.benzinga.com/news/financing/24/12/42506690/super-micro-seeks-to-raise-capital-via-equity-and-debt" rel="noreferrer noopener">enlisted Evercore to</a> assist in raising capital.
The effort aims to avoid a potential delisting after the company missed its August deadline for filing its annual financial report while reviewing internal financial controls.
The company is considering private investment in public equity (PIPE) funding, which could attract interest from private equity firms. While PIPE funding provides a faster capital-raising method, it dilutes existing shareholders&#8217; equity.
Concerns still need to be made about the profitability of Super Micro&#8217;s AI-optimized servers due to reliance on high-end chips from suppliers like Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Super Micro&#8217;s auditor, Ernst &amp; Young, resigned in October over governance concerns. This led to a sharp decline in stock value and prompted an independent committee to investigate. By December, the committee found no evidence of misconduct, spurring a 30% rise in Super Micro&#8217;s stock.
The company appointed BDO USA as its new auditor to address delisting risks, submitted a compliance plan to Nasdaq, and began searching for a new finance chief based on the committee&#8217;s recommendations.
Super Micro, which faced scrutiny from a Hindenburg Research report and a U.S. Department of Justice probe, has until February 25 to file its delayed financial reports.
Super Micro Computer missed the revenue estimates for the last two quarters and the adjusted EPS consensus for the last quarter.
In July 2024, Super Micro Computer <a target="_blank" href="https://www.benzinga.com/news/24/07/39847680/whats-going-on-with-super-micro-computer-shares-today" rel="noreferrer noopener">became a component</a> of the Nasdaq-100 Index and the Nasdaq-100 Equal Weighted Index, replacing Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>).
At that time, CEO Charles Liang highlighted Super Micro&#8217;s eco-friendly initiatives and AI growth opportunities during an interview with CNBC&#8217;s Jim Cramer.
Liang showcased the potential of their &#8220;liquid cooling&#8221; and &#8220;green computer&#8221; technologies to cut carbon emissions and reduce customer expenses.
He also shared his confidence in the transformative power of AI, predicting it could have a more significant impact than the industrial revolution.
The Nasdaq-100 Index underpins the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which seeks to deliver investment results mirroring the index&#8217;s performance before expenses.
Price Action: SMCI stock closed lower by 8.26% to $33.44 on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42514450/grindrs-expanding-lgbtq-market-and-20-revenue-growth-impresses-goldman-sachs" target="_blank" rel="noreferrer noopener">Grindr&#8217;s Expanding LGBTQ+ Market and 20% Revenue Growth Impresses Goldman Sachs</a></li>
</ul>
Photo via Company

AXON

MRNA

MSTR

PLTR

SMCI

Super Micro Drops Below 50-Day Average, Faces Nasdaq 100 Removal Just Months After Entry

On Friday, Nasdaq Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) annual reconstitution of the Nasdaq-100 Index will become effective before the market <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42494812/annual-changes-to-the-nasdaq-100-index" rel="noreferrer noopener">opens on December 23</a>.
Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) was&nbsp;removed&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42495649/microstrategy-palantir-axon-added-to-nasdaq-100-super-micro-computer-moderna-illumina-exit-the-index" rel="noreferrer noopener">from the index</a>. Year to date, the stock has increased around 8%, underperforming iShares Core S&amp;P Mid-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IJH#NYSE">IJH</a>).
The provider of DNA sequencing and array-based technologies has been in the news due to its controversial multi-billion dollar deal to acquire cancer test maker Grail Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/24/09/40688420/european-court-rules-in-favor-of-illumina-in-fight-against-probe-into-grail-deal-asks-not-to-pay-478" rel="noreferrer noopener">European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1.png" alt="" class="wp-image-694387" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Nearly four years after pitching for&nbsp;Grail,&nbsp;Illumina finally separated the&nbsp;<a target="_blank" href="https://www.benzinga.com/m-a/24/09/40688420/european-court-rules-in-favor-of-illumina-in-fight-against-probe-into-grail-deal-asks-not-to-pay-478" rel="noreferrer noopener">cancer blood test developer</a>.&nbsp;To expand its reach in single-cell analysis and&nbsp;multiomics research, Illumina <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39714633/illumina-buys-fluent-biosciences-to-gain-stronger-foothold-in-single-cell-analysis" rel="noreferrer noopener">acquired privately-held</a> Fluent BioSciences.
Also in March, activist investor&nbsp;Carl Icahn opted against pursuing a fresh challenge to Illumina&#8217;s board, which spares the U.S. gene sequencing company from facing its second proxy battle in consecutive years.&nbsp;
Previously, Icahn had expressed intentions to remove additional directors from Illumina&#8217;s board, attributing the company&#8217;s substantial market value decline and the ill-fated $7.1 billion Grail acquisition to mismanagement by the <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/03/37671511/gene-sequencing-firm-illumina-escapes-carl-icahns-second-proxy-battle-amid-grail-divestment-effort" rel="noreferrer noopener">existing board members</a>.&nbsp;
Most recently, Illumina reported third-quarter&nbsp;adjusted EPS of $1.14, beating the consensus of $0.88, with sales&nbsp;of $1.08 billion, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41727185/illumina-reports-financial-results-for-third-quarter-of-fiscal-year-2024" rel="noreferrer noopener">consensus of $1.08 billion</a>.
&#8220;During the third quarter, the Illumina team delivered strong operating results, and revenue met our expectations,&#8221; said&nbsp;Jacob Thaysen, Chief Executive Officer.
&#8220;The near-term macroeconomic environment remains constrained, and we are slightly lowering our 2024 revenue guidance,&#8221; Thaysen added.
Price Action: ILMN stock is down 0.12% at $143.70 at the last check on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42514376/whats-going-on-moderna-stock-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Moderna Stock On Monday?</a></li>
</ul>
Photo via Shutterstock

GRAL

NDAQ

What's Going On With Illumina Stock On Monday?

Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock is trading lower on Monday. The company is expected to be removed from the Nasdaq 100 Index later this month. Here&#8217;s what you <a href="https://www.benzinga.com//node/42506977">need to know</a>.
What To Know: Super Micro is one of three companies set to be booted from the Nasdaq 100 Index on Dec. 23 as part of the index&#8217;s annual changes.
The changes will take effect before the market opens on Dec. 23. The other companies set to be removed from the index, include Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) and Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>). 
The Nasdaq is set to add Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and Axon Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) to the index.
What Else: Super Micro has faced delays in filing its earnings for the 2024 fiscal year as well as the first quarter of the 2025 fiscal year. The company originally cited multiple reasons for the delay, including the need to find a new auditor after Ernst &amp; Young, the company&#8217;s former auditor, resigned due to governance control issues, and the need to review its internal control systems.
Super Micro has since appointed BDO USA as its independent auditor. In addition, the company&#8217;s special committee review found no evidence of misconduct.
 Lastly, the company is <a href="https://www.benzinga.com//node/42506690">working</a> with Evercore to raise its capital. The company is considering multiple options in order to achieve this, such as, a private investment in public equity.
Related Link: <a href="https://www.benzinga.com/insights/options/24/12/42510375/what-the-options-market-tells-us-about-on-holding">What the Options Market Tells Us About On Holding</a>
SMCI Price Action: At the time of writing, Super Micro stock is trading 6.75% lower at $33.98, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Shutterstock

What's Going On With Super Micro Computer Shares Monday?

Grail 2024 revenue guidance range above consensus

Tempering Positive Sentiment Of AI In Biotech

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA's vast potential. Given this backdrop, investing in fundamentally sound genomics stocks like Illumina (ILMN), BioNTech (BNTX), and Bio-Techne Corp. (TECH) could be beneficial. Read more… Genomics, the study of genes and their functions, is no longer just a niche scientific pursuit; it's reshaping how we understand human health and disease. Over the last two decades, gene sequencing costs have <a href="https://3billion.io/blog/whole-genome-sequencing-costs-2024-new-prices-and-future-projections">dropped significantly</a>, making it more affordable, accurate, and faster to map a person's entire genome. This shift is accelerating discoveries and laying the foundation for a new era of personalized medicine, where treatments are tailored to an individual's genetic profile.
As this field continues to evolve, companies like Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>), BioNTech SE (<a href="https://stocknews.com/stock/BNTX/">BNTX</a>), and Bio-Techne Corporation (<a href="https://stocknews.com/stock/TECH/">TECH</a>) are leading the charge, unlocking the secrets of DNA to revolutionize healthcare.
The genomics industry is set for explosive growth, with the global market projected to grow from $39.53 billion in 2024 to $157.47 billion by 2033 at a <a href="https://www.biospace.com/genomics-market-size-to-hit-usd-157-47-billion-by-2033#:~:text=The%20global%20genomics%20market%20size,period%20(2024%2D2033).">CAGR of 16.6%</a>. The sales of next-generation genomic medicines alone are expected to <a href="https://ascent.usbank.com/private-capital-management/ascent-resources-and-insights/investment-strategies/investing-in-genomics.html">hit $84 billion by 2028</a>, driven by successful clinical trials and the increasing demand for innovative treatments.
These advancements are fueling opportunities for investors, as companies at the forefront of this revolution are well-positioned to reap the rewards. With that in mind, let's look at the fundamentals of the top <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: Bio-Techne Corporation (<a href="https://stocknews.com/stock/TECH/">TECH</a>)
TECH develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets globally. It operates through two segments: Protein Sciences; and Diagnostics and Genomics.
On December 10, the company announced a partnership with MedSanTek, which will serve as the distributor for TECH's R&amp;D Systems, Novus, Tocris, ProteinSimple, Advanced Cell Diagnostics (ACD), and Asuragen brands across Turkey. This agreement is expected to enhance revenues and broaden the company's presence in the region.
On November 18, TECH announced a strategic partnership with ALZpath, Inc. to drive advancements in neurodegenerative disease research and treatment, including Alzheimer's. The collaboration leverages Bio-Techne's Ella&#x2122; fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay.
TECH's trailing 12-month gross profit margin of 65.99% is 13.4% higher than the industry average of 58.20%. Likewise, its EBIT and levered FCF margins of 20.81% and 19.84% are considerably higher than their respective industry averages of 2.72% and 1.96%.
During the fiscal first quarter that ended September 30, 2024, TECH's net sales increased 4.5% year-over-year to $289.46 million. Its adjusted gross margin grew marginally from the year-ago value to $199.59 million. Also, the company's non-GAAP net earnings amounted to $67.53 million or $0.42 per share, indicating an increase of 2.3% and 2.4% year-over-year, respectively.
The consensus revenue estimate of $318.04 million for the fiscal third quarter (ending March 2025) represents a 4.8% year-over-year growth. The consensus <a href="https://investopedia.com/terms/e/eps.asp">EPS</a> estimate of $0.51 for the ongoing quarter represents a 7.2% increase from the same period last year.
Shares of TECH have gained 8.7% over the past nine months to close the last trading session at $73.79.
TECH's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has a B grade for Growth and Quality. TECH is ranked #34 among 336 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/TECH/">Click here</a> to access additional TECH ratings (Value, Momentum, Stability, and Sentiment).
Stock #2: BioNTech SE (<a href="https://stocknews.com/stock/BNTX/">BNTX</a>)
Based in Mainz, Germany, BNTX is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, BNT112, BNT113, BNT115, and BNT116.
On November 13, BNTX announced the acquisition of Biotheus, a clinical-stage biotechnology company focused on innovative antibody therapies for oncological and inflammatory diseases. This strategic move aligns with BNTX's global oncology strategy, granting it full rights to BNT327/PM8002, a bispecific antibody with the potential to surpass existing checkpoint inhibitors for solid tumors.
Moreover, through this acquisition, the company aims to enhance its ability to develop, produce, and commercialize next-generation bispecific antibodies and innovative treatment combinations.
BNTX's trailing 12-month gross profit margin of 84.31% is 44.9% higher than the industry average of 58.20%. In addition, its trailing-12-month levered FCF margin of 46.24% compares to the industry average of 1.96%.
For the fiscal third quarter that ended September 30, 2024, BNTX's total revenues increased 39% year-over-year to €1.24 billion ($1.28 billion). Its operating income came in at €10.50 million ($10.82 million). The company's net profit and earnings per share for the period stood at €198.10 million ($204.19 million) and €0.81, up 23.3% and 22.7% year-over-year, respectively.
Analysts predict BNTX's EPS and revenue for the fourth quarter (ended December 2024) to come in at $0.52 and $1.19 billion, respectively. Over the past six months, the stock has surged 45% to close the last trading session at $115.79.
It is no surprise that BNTX has an overall rating of B, equating to Buy in our POWR Ratings system. It also has a B grade for Value, Sentiment, and Quality. Out of 336 stocks in the same industry, it is ranked #19.
In addition to the POWR Rating grades I've just highlighted, you can see BNTX's Growth, Momentum, and Stability ratings <a href="https://stocknews.com/stock/BNTX/">here</a>.
Stock #1: Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>)
ILMN offers sequencing- and array-based solutions for large-scale genetic and genomic analysis. It operates through the Core Illumina and GRAIL segments. It provides sequencing and array-based instruments and consumables, whole-genome sequencing kits, genotyping, NIPT, and product support services.
On November 19, the company unveiled plans to launch TruSight Oncology 500 v2 (TSO 500 v2), an upgraded version of its flagship cancer research assay designed for comprehensive genomic profiling (CGP). This advanced assay evaluates hundreds of genes across all variant classes and immuno-oncology biomarkers, providing critical insights for therapy selection research. Currently in development, TSO 500 v2 is set for a global release in mid-2025.
ILMN's trailing 12-month gross profit margin of 67.61% is 16.2% higher than the industry average of 58.20%. Likewise, its 16.63% trailing-12-month EBITDA margin is 186.5% above the industry average of 5.80%. Also, its trailing 12-month levered FCF margin of 9.64% compares to the industry average of 1.96%.
In the third quarter that ended September 29, 2024, ILMN reported a total revenue of $1.08 billion with a gross margin of 68.9%. Its non-GAAP operating profit rose 162.4% from the year-ago value to $244 million. The company's non-GAAP net income and EPS came in at $181 million and $1.14, indicating an improvement of 248.1% and 245.5% year-over-year, respectively.
Street expects ILMN's EPS for the fiscal fourth quarter (ended December 2024) to increase 552.5% year-over-year to $0.91, while its revenue is forecasted to be $1.07 billion. Moreover, it surpassed the consensus revenue estimates in each of the trailing four quarters, which is impressive.
The stock has gained 29.2% over the past six months to close the last trading session at $136.01.
ILMN's POWR Ratings reflect this promising outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
It has an A grade for Growth and a B for Quality. Within the Biotech industry, it is ranked #17. To see the other ILMN ratings for Value, Momentum, Stability, and Sentiment, <a href="https://stocknews.com/stock/ILMN/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
<hr />
BNTX shares were trading at $120.51 per share on Monday afternoon, up $4.72 (+4.08%). Year-to-date, BNTX has gained 5.76%, versus a 2.16% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/bntx-ilmn-tech-3-genomic-stocks-unlocking-the-secrets-of-dna/>3 Genomic Stocks Unlocking the Secrets of DNA</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Genomic Stocks Unlocking the Secrets of DNA

Leerink Partners analyst Puneet Souda has maintained their bullish stance on ILMN stock, giving a Buy rating on January 10. Puneet Souda has given ...

Illumina's Promising Growth Trajectory: Buy Rating Backed by Strategic Positioning and Market Innovations

Welcome to "Sector Spotlight," where The Fly looks at a new industry every week and highlights its happenings. PHARMA SECTOR NEWS:&nbsp;In 2024, dr...

Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations

Baron Focused Growth Fund Q4 2024 Shareholder Letter

Life sciences stocks fall on NIH funding concerns

Dividends And Dynamite: 10 High-Yield Blue-Chip Bargains You Don't Want To Miss

ABBV

ABCL

ABNB

ACGL

AMGN

ANSS

ASML

BCAP

BIRK

BNTX

BRKR

BROE

CGON

CSGP

DNUT

FIGS

GILD

GOOG

GOOGL

IBKR

IDXX

IRDM

ITCI

MRKR

MSCI

NVSEF

ONON

PACB

PPTDF

QGEN

REGN

RHHBY

RHHVF

RLAY

RVTY

SHOP

SPOT

TCGGY

TCHBF

TECH

TSLA

VRSK

Press Releases

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications

Illumina To Webcast Upcoming Investor Conference

Annual Changes to the Nasdaq-100 Index®

Ovation.io and Illumina Collaborate to Advance Genomic Data Research

Illumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applications

Illumina to Announce Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 6, 2025

Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples

Illumina and NVIDIA collaborate to decode biology and propel precision health

Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025

MYGN

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Illumina

Noticias

Últimas noticias sobre Illumina (NASDAQ:ILMN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL